XML 17 R7.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES      
Net loss   $ (12,590) $ (9,094)
Adjustments to reconcile net loss to net cash used in operating activities:      
Stock-based compensation expense   617  
Shares issued in connection with Amgen Agreement     1,353
Acquisition of technology in connection with Amgen Agreement     5,000
Issuance date fair-value of anti-dilution liability     1,639
Change in fair value of anti-dilution right liability $ 11   11
Changes in operating assets and liabilities:      
Prepaid expenses and other assets   697 15
Accounts payable   317 455
Accrued expenses and other current liabilities   193 32
Net cash used in operating activities   (10,766) (589)
CASH FLOWS FROM INVESTING ACTIVITIES      
Acquisition of technology in connection with Amgen Agreement     (5,000)
Net cash used in investing activities     (5,000)
CASH FLOWS FROM FINANCING ACTIVITIES      
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs     14,784
Proceeds from issuance of common stock in initial public offering, net of issuance costs and underwriting fees   97,080  
Proceeds from the early exercise of stock options in exchange for restricted common stock   300  
Proceeds from exercise of stock options   100  
Net cash provided by financing activities   97,480 14,784
Net increase in cash, cash equivalents and restricted cash   86,714 9,195
Cash and restricted cash at beginning of period   76,000 618
Cash, cash equivalents and restricted cash at end of period 9,813 162,714 9,813
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:      
Conversion of convertible preferred stock into common stock upon closing of initial public offering   124,728  
Accretion of redeemable convertible preferred stock to redemption value $ 70   70
Issuance date fair value of preferred stock tranche obligation     7,350
Deferred offering costs included in accounts payable and accrued expenses and other current liabilities   $ 1,628  
Common stock issued in connection with Amgen Agreement     $ 1,353